← Back to patent-cliff list
Glycopyrrolate/indacaterol (AeroRX Therapeutics/HCmed)
Tier C — Watch / tradeGlycopyrrolate/indacaterol (AeroRX Therapeutics/HCmed)
AeroRx Therapeutics Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：mAChRs, β-adrenoceptors
Indications (approved)：Chronic obstructive pulmonary disease
Regional status
US
-
EU
Phase II
2025-01-15
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Glycopyrrolate/indacaterol (AeroRX Therapeutics/HCmed)?
Approved indications include: Chronic obstructive pulmonary disease.
When does the Glycopyrrolate/indacaterol (AeroRX Therapeutics/HCmed) patent expire?
No public expiry year is available for Glycopyrrolate/indacaterol (AeroRX Therapeutics/HCmed) yet; this page updates once verified.
How do I get a quote for Glycopyrrolate/indacaterol (AeroRX Therapeutics/HCmed) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01